| Title |
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, September 2010
|
| DOI | 10.1007/s00280-010-1470-2 |
| Pubmed ID | |
| Authors |
Masashi Kanai, Kenichi Yoshimura, Masanori Asada, Atsushi Imaizumi, Chihiro Suzuki, Shigemi Matsumoto, Takafumi Nishimura, Yukiko Mori, Toshihiko Masui, Yoshiya Kawaguchi, Kazuhiro Yanagihara, Shujiro Yazumi, Tsutomu Chiba, Sushovan Guha, Bharat B. Aggarwal |
| Abstract |
Curcumin, a plant-derived natural polyphenol, could be a promising anti-cancer drug and shows synergic effects with cytotoxic agents. We evaluated the safety and feasibility of combination therapy using curcumin with gemcitabine-based chemotherapy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 215 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 213 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 32 | 15% |
| Student > Ph. D. Student | 27 | 13% |
| Student > Bachelor | 22 | 10% |
| Student > Master | 21 | 10% |
| Other | 18 | 8% |
| Other | 36 | 17% |
| Unknown | 59 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 55 | 26% |
| Biochemistry, Genetics and Molecular Biology | 27 | 13% |
| Agricultural and Biological Sciences | 25 | 12% |
| Chemistry | 9 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 4% |
| Other | 25 | 12% |
| Unknown | 65 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 October 2023.
All research outputs
#2,345,143
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#58
of 2,501 outputs
Outputs of similar age
#8,890
of 99,208 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#1
of 25 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 99,208 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.